Ads
related to: statins don't increase survivability due to cancer cells research pdfnexlizet.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
IL-33 signals the body to produce other immune system cells when an injury or infection occurs. ... The mechanism through which statins affect cancer outcomes isn’t clear either. In Demehri’s ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.
Clinical studies have been conducted on the use of statins in dementia, [215] lung cancer, [216] nuclear cataracts, [217] hypertension, [218] [219] and prostate cancer [220] and breast cancer. [221] There is no high quality evidence that statins are useful for pneumonia . [ 222 ]
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88; NADPH-dependent, EC 1.1.1.34) of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids.
For premium support please call: 800-290-4726 more ways to reach us
Ad
related to: statins don't increase survivability due to cancer cells research pdf